Latest From Vivus Inc.
Claims that Vivus' obesity drug helps patients lose weight faster than diet and exercise alone are false and misleading because the clinical studies were not designed to evaluate the rate of weight loss over time, Office of Prescription Drug Promotion says in untitled letter; Vivus says it is finalizing revisions to its promotions.
Fixed-dose combination of phentermine and topiramate is FDA-approved for chronic, long-term use, but the average duration in the real world is only about 2.1 months, which is reassuring for Qsymia’s cardiovascular safety, according to a new retrospective claims study.
Public Company Edition: An SEC complaint alleges that the company, Opko CEO Frost and co-defendants bought penny stocks, pumped up their value, then dumped shares for sizeable profits. Also, Pfizer and Retrophin float debt offerings, while Zealand sells royalties and milestone fees to raise cash.
Full results from a large cardiovascular outcomes study with Belviq show the Eisai/Arena obesity drug was not associated with higher such risk versus placebo, but neither did it show benefits in reducing major CV events, leaving uncertainty over its increased uptake amid lingering issues around diabetes and valvulopathy risks.
- Therapeutic Areas
- Gynecological, Urological
- Metabolic Disorders
- Respiratory, Pulmonary
- North America
- Parent & Subsidiaries
- Vivus Inc.
- Senior Management
Thomas B King, Interim CEO
Mark K Oki, CFO & Chief Accounting Officer
Deborah W Larsen, PhD, Chief Commercial Officer
John L Slebir, SVP, Bus. Dev. & General Counsel
Santosh T Varghese, MD, CMO
- Contact Info
Phone: (650) 934-5200
900 E. Hamilton Ave
Campbell, CA 95008
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.